oa SA Pharmaceutical Journal - Drug info - new product focus

Volume 77, Issue 3
  • ISSN : 2221-5875
  • E-ISSN: 2220-1017



Byetta® has been approved for use as adjunctive therapy to improve glycaemic control in patients with type 2 diabetes mellitus who are taking either metformin or a sulphonylurea or both, and who have not achieved glycaemic control.

Loading full text...

Full text loading...


Article metrics loading...


This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error